Alphonse Ambrosia, DO
Interventional Cardiology · Mesa, AZNPI 1598736126
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,614 of the $17,745 with a category attached, or 76.7%. It is spread thinly across 58 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations.
Across 517 payments — averaging $34.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Abbott$3K
- Edwards Lifesciences$2K
- Medtronic$2K
- AOP Health US, LLC$963
- Corindus Inc.$800
- plus $7K from 52 others
Across 14 payments — averaging $11,574 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$103K
- Abbott$59K
What the payments were for
- Consulting fees$1,5008%
- Travel & lodging$2,48014%
- Food & beverage$13,61477%
- Education$1121%
- Other$390%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rapiblyk$1,885
- AVVIGO Guidance System$1,500
- PASCAL$1,005
- CorPath GRX$800
- SYMPLICITY G3$311
- OPTIMIZER$262
- CoreValve Evolut$257
- FFRct$256
- Impella$235
- SAPIEN 3 Ultra RESILIA$222
- Resolute$191
- COREVALVE EVOLUT R$180
- CARDIOMEMS$173
- Mitra Clip system$166
- LifeSPARC System$156
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$149
- MitraClip$143
- PORTICO$141
- AMPLATZER AMULET$138
- GENERAL - THERAPIES$131
How this compares
$17,745 in reported general payments places this provider in the 65th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 358 | $456,986 |
| XareltoRivaroxaban | 88 | $108,570 |
| EntrestoSacubitril/Valsartan | 80 | $94,579 |
| BrilintaTicagrelor | 56 | $39,270 |
| Repatha SureclickEvolocumab | 39 | $38,073 |
| MultaqDronedarone Hcl | 13 | $31,176 |
| FarxigaDapagliflozin Propanediol | 18 | $27,333 |
| Praluent PenAlirocumab | 11 | $15,774 |
| ClopidogrelClopidogrel Bisulfate | 396 | $5,423 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 13 | $5,148 |
| Metoprolol Succinate | 347 | $4,788 |
| Ranolazine ErRanolazine | 44 | $4,630 |
| Verapamil SrVerapamil Hcl | 19 | $3,388 |
| Rosuvastatin Calcium | 220 | $3,247 |
| Potassium Chloride | 79 | $2,831 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $340 | $456,986358 claims |
| Johnson & JohnsonXarelto | $175 | $108,57088 claims |
| NovartisEntresto | $448 | $94,57980 claims |
| AstraZenecaBrilinta, Farxiga | $30 | $66,60374 claims |
| Sanofi-aventis U.S. LLCMultaq | $197 | $31,17613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Mesa
- Faraj KargoliMesa$115K
- Nachiket PatelMesa$107K
- Satya Prakash AtmakuriMesa$41K
- Robert CandipanMesa$32K
- I-Hui ChiangMesa$27K
- Paul SorajjaPhoenix$1.1M
- Hursh NaikAvondale$781K
- Thomas WaggonerTucson$617K
- Timothy ByrnePhoenix$614K
- Haidar YassinPhoenix$434K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.